The world’s smallest pacemaker.1

A pacemaker with Sleep Apnea Monitoring. Extending the boundaries in cardiovascular disease management.
REPLY-200-DR_MicroPort_2018

Featuring

SafeR™

Dramatically reduces unnecessary RV pacing in all pacemaker patients, including AV block patients

Featuring

SAM

Sleep Apnea Monitoring measures respiration pauses and reduction in respiration.

Featuring

Dual Sensor

Designed to physiologically modulate heart rhythm by combining Accelerometer and Minute Ventilation sensors.

Reply 200 automatically screens patients at risk of severe sleep apnea, featuring a suite of algorithms designed to prevent serious cardiovascular comorbidities.

12 years longevity in only 8 cc.

The world’s smallest dual-chamber pacemaker with no compromise on longevity.1–3

 

 
 

Built on proven technology

Reply 200 is built on the heritage of Sorin pacemaker technology. The Reply pacemaker platform has been proven in practice.4

Reply pacemakers:

  • 99.96% cumulative survival 6 years after implantation

Beflex leads:

  • 99.94% cumulative survival 5 years after implantation

Reply 200 is built on the Reply platform.

Powered by intelligent algorithms.

SafeR™

  • Advanced AV management for increased protection5,7–13
  • Reduces RV pacing in SND and AVB patients5
  • Manages ALL types of AV blocks at rest and at exercise1,5
  • Adds 2 YEARS of device longevity12,13
  • Unique AV block diagnosis
 

Sleep Apnea Monitoring

 

Early detection, long-term risk reduction2,6,14–18

  • Reliable screening to detect severe sleep apnea with high specificity (85%) and high sensitivity (89%)6
  • Correlated with gold standard Apnea–Hypopnea Index*6
  • Designed to monitor the evolution of sleep apnea2

*Apnea Hypopnea Index (AHI) = number of events/number of hours of sleep

 

Dual Sensor

  • Adjust to metabolic needs. Exercise safely
  • Designed to physiologically modulate the heart rhythm by combining Accelerometer and Minute Ventilation sensors
 

 

This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative.

Related products:
Orchestra Plus Programmer; Leads; Vega; Xfine

References

  1. Competition technical manuals (dual-chamber pacemakers) available online.
  2. Sorin implant manuals (Reply 200 – U071 – U072) available at www.microportmanuals.com
  3. Reply 200 with typical conditions using SafeR: 50% A pacing, 5% V pacing, SAM ON, 60 bpm, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics ON, Sensors ON.
  4. Sorin Group; Product Performance Report. November 2014.
  5. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). European Heart Journal. 2015;36:151–57.
  6. Defaye P, et al. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: The DREAM European study. Heart Rhythm. 2014; 11: 842–48.
  7. Andersen HR, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210–6.
  8. Skanes AC, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing (CTOPP). J Am Coll Cardiol. 2001;38:167–72.
  9. Nielsen J, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003;42:614–23.
  10. Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003; 107: 2932–37.
  11. Wilkoff BL, Cook JR, Epstein AE et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID trial). JAMA. 2002; 288: 3115–23.
  12. Stockburger M, Defaye P, Boveda S et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016; 18:739–46.
  13. Benkemoun H, et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012;35:403–08.
  14. Gottlieb DJ, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352–60.
  15. Mehra R, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173:910–16.
  16. Monahan K, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110:369–72.
  17. Kanagala R, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107:2589–94.
  18. Ng CY, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108:47–51.
Exemplary message

By continuing to browse this website you confirm that you are a healthcare professional.